Avidity biosciences announces 2024 corporate priorities and catalysts for next stage of growth

Avidity plans to initiate global phase 3 harbor ™ trial of aoc 1001 for dm1 mid-2024 company to report data from all three ongoing clinical programs in 2024  -- aoc 1001 data for dm1 in q1, aoc 1020 data for fshd in q2, and aoc 1044 data for dmd44 in 2h -- avidity to advance wholly-owned and partnered cardiology programs toward clinical development avidity appoints eric b. mosbrooker as chief strategy officer san diego , jan. 5, 2024 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced its 2024 corporate priorities and catalysts for the next stage of growth.
RNA Ratings Summary
RNA Quant Ranking